Methods and Applications of Statistics in Clinical Trials, Volume 1
eBook - ePub

Methods and Applications of Statistics in Clinical Trials, Volume 1

Concepts, Principles, Trials, and Designs

  1. English
  2. ePUB (mobile friendly)
  3. Available on iOS & Android
eBook - ePub

Methods and Applications of Statistics in Clinical Trials, Volume 1

Concepts, Principles, Trials, and Designs

About this book

A complete guide to the key statistical concepts essential for the design and construction of clinical trials

As the newest major resource in the field of medical research, Methods and Applications of Statistics in Clinical Trials, Volume 1: Concepts, Principles, Trials, and Designs presents a timely and authoritative reviewof the central statistical concepts used to build clinical trials that obtain the best results. The referenceunveils modern approaches vital to understanding, creating, and evaluating data obtained throughoutthe various stages of clinical trial design and analysis.

Accessible and comprehensive, the first volume in a two-part set includes newly-written articles as well as established literature from the Wiley Encyclopedia of Clinical Trials. Illustrating a variety of statistical concepts and principles such as longitudinal data, missing data, covariates, biased-coin randomization, repeated measurements, and simple randomization, the book also provides in-depth coverage of the various trial designs found within phase I-IV trials. Methods and Applications of Statistics in Clinical Trials, Volume 1: Concepts, Principles, Trials, and Designs also features:

  • Detailed chapters on the type of trial designs, such as adaptive, crossover, group-randomized, multicenter, non-inferiority, non-randomized, open-labeled, preference, prevention, and superiority trials
  • Over 100 contributions from leading academics, researchers, and practitioners
  • An exploration of ongoing, cutting-edge clinical trials on early cancer and heart disease, mother-to-child human immunodeficiency virus transmission trials, and the AIDS Clinical Trials Group

Methods and Applications of Statistics in Clinical Trials, Volume 1: Concepts, Principles, Trials, and Designs is an excellent reference for researchers, practitioners, and students in the fields of clinicaltrials, pharmaceutics, biostatistics, medical research design, biology, biomedicine, epidemiology,and public health.

Trusted by 375,005 students

Access to over 1.5 million titles for a fair monthly price.

Study more efficiently using our study tools.

Information

Publisher
Wiley
Year
2014
Print ISBN
9781118304730
eBook ISBN
9781118595916
Edition
1

Chapter 1

Absolute Risk Reduction

Robert Newcomb

1.1 Introduction

Many response variables in clinical trials are binary: the treatment was successful or unsuccessful; the adverse effect did or did not occur. Binary variables are summarized by proportions, which may be compared between different arms of a study by calculating either an absolute difference of proportions or a relative measure, the relative risk or the odds ratio. In this article we consider several point and interval estimates for the absolute difference between two proportions, for both unpaired and paired study designs. The simplest methods encounter problems when numerators or denominators are small; accordingly, better methods are introduced. Because confidence interval methods for differences of proportions are derived from related methods for the simpler case of the single proportion, which itself can also be of interest in a clinical trial, this case is also considered in some depth. Illustrative examples relating to data from two clinical trials are shown.

1.2 Preliminary Issues

In most clinical trials, the unit of data is the individual, and statistical analyses for efficacy and safety outcomes compare responses between the two (or more) treatment groups. When subjects are randomized between these groups, responses of subjects in one group are independent of those in the other group. This leads to unpaired analyses. Crossover and split-unit designs require paired analyses. These have many features in common with the unpaired analyses and will be described in the final section.
Thus, we study n1 individuals in group 1 and n2 individuals in group 2. Usually, all analyses are conditional on n1 and n2. Analyses conditional on n1 and n2 would also be appropriate in other types of prospective studies or in cross-sectional designs. (Some hypothesis testing procedures such as the Fisher exact test are conditional also on the total number of “successes” in the two groups combined. This alternative conditioning is inappropriate for confidence intervals for a difference of proportions; in particular in the event that no successes are observed in either group, this approach fails to produce an interval.) The outcome variable is binary: 1 if the event of interest occurs, 0 if it does not. (We do not consider here the case of an integer-valued outcome variable; typically, this involves the number of episodes of relapse or hospitalization, number of accidents, or similar events occurring within a defined follow-up period. Such an outcome would instead be modeled by the Poisson distribution.) We observe that r1 subjects in group 1 and r2 subjects in group 2 experience the event of interest. Then the proportions having the event in the two groups are given by p1 = r1/n1 and p2 = r2/n2. If responses in different individuals in each group are independent, then the distribution of the number of events in each group is binomial.
Several effect size measures are widely used for comparison of two independent proportions:
Difference of proportions p1p2
Ratio of proportions (risk ratio or relative risk) p1/p2
Odds ratio (p1/(1 − p1))/(p2/(1 − p2))
In this article we consider in particular the difference between two proportions, p1p2, as a measure of effect size. This is variously referred to as the absolute risk reduction, risk difference, or success rate difference. Other articles in this work describe the risk ratio or relative risk and the odds ratio. We consider both point and interval estimates, in recognition that “confidence intervals convey information about magnitude and precision of effect simultaneously, keeping these two aspects of measurement closely linked” [1]. In the clinical trial context, a difference between two proportions is often referred to as an absolute risk reduction. However, it should be borne in mind that any term that includes the word “reduction” really presupposes that the direction of the difference will be a reduction in risk—such terminology becomes awkward when the anticipated benefit does not materialize, including the nonsignificant case when the confidence interval for the difference extends beyond the null hypothesis value of zero. The same applies to the relative risk reduction, 1 − p1/p2. Whenever results are presented, it is vitally important that the direction of the observed difference should be made unequivocally clear. Moreover, sometimes confusing labels are used, which might be interpreted to mean something other than p1p2; for example, Hashemi et al. [2] refer to p1p2 as attributable risk. It is also vital to distinguish between relative and absolute risk reduction.
In clinical trials, as in other prospective and cross-sectional designs already described, each of the three quantities we have discussed may validly be used as a measure of effect size. The risk difference and risk ratio compare two proportions from different perspectives. A halving of risk will have much greater population impact for a common outcome than for an infrequent one. Schechtman [3] recommends that both a relative and an absolute measure should always be reported, with appropriate confidence intervals.
The odds ratio is discussed at length by Agresti [4]. It is widely regarded as having a special preferred status on account of its role in retrospective case-control studies and in logistic regression and meta-analysis. Nevertheless, it should not be regarded as having gold standard status as a measure of effect size for the 2 × 2 table [3,5].

1.3 Point and Interval Estimates for a Single Proportion

Before considering the difference between two independent proportions in detail, we first consider some of the issues that arise in relation to the fundamental task of estimating a single proportion. These issues have repercussions for the comparison of proportions because confidence interval methods for p1p2 are generally based closely on those for proportions. The single proportion is also relevant to clinical trials in its own right. For example, in a clinical trial comparing surgical versus conservative management, we would be concerned with estimating the incidence of a particular complication of surgery such as postoperative bleeding, even though there is no question of obtaining a contrasting value in the conservative group or of formally comparing these.
The most commonly used estimator for the population proportion π is the familiar empirical estimate, namely, the observed proportion p = r/n. Given n, the random variable R denoting the number of subjects i...

Table of contents

  1. Cover
  2. Half Title page
  3. Title page
  4. Copyright page
  5. Contributors
  6. Preface
  7. Chapter 1: Absolute Risk Reduction
  8. Chapter 2: Accelerated Approval
  9. Chapter 3: AIDS Clinical Trials Group (ACTG)
  10. Chapter 4: Algorithm-Based Designs
  11. Chapter 5: Alpha-Spending Function
  12. Chapter 6: Application of New Designs in Phase I Trials
  13. Chapter 7: ASCOT Trial
  14. Chapter 8: Benefit/Risk Assessment in Prevention Trials
  15. Chapter 9: Biased Coin Randomization
  16. Chapter 10: Biological Assay, Overview
  17. Chapter 11: Block Randomization
  18. Chapter 12: Censored Data
  19. Chapter 13: Clinical Data Coordination
  20. Chapter 14: Clinical Data Management
  21. Chapter 15: Clinical Significance
  22. Chapter 16: Clinical Trial Misconduct
  23. Chapter 17: Clinical Trials, Early Cancer and Heart Disease
  24. Chapter 18: Cluster Randomization
  25. Chapter 19: Coherence in Phase I Clinical Trials
  26. Chapter 20: Compliance and Survival Analysis
  27. Chapter 21: Composite Endpoints in Clinical Trials
  28. Chapter 22: Confounding
  29. Chapter 23: Control Groups
  30. Chapter 24: Coronary Drug Project
  31. Chapter 25: Covariates
  32. Chapter 26: Crossover Design
  33. Chapter 27: Crossover Trials
  34. Chapter 28: Diagnostic Studies
  35. Chapter 29: DNA Bank
  36. Chapter 30: Up-and-Down and Escalation Designs
  37. Chapter 31: Dose Ranging Crossover Designs
  38. Chapter 32: Flexible Designs
  39. Chapter 33: Gene Therapy
  40. Chapter 34: Global Assessment Variables
  41. Chapter 35: Good Clinical Practice (GCP)
  42. Chapter 36: Group-Randomized Trials
  43. Chapter 37: Group Sequential Designs
  44. Chapter 38: Hazard Ratio
  45. Chapter 39: Large Simple Trials
  46. Chapter 40: Longitudinal Data
  47. Chapter 41: Maximum Duration and Information Trials
  48. Chapter 42: Missing Data
  49. Chapter 43: Mother to Child Human Immunodeficiency Virus Transmission Trials
  50. Chapter 44: Multiple Testing in Clinical Trials
  51. Chapter 45: Multicenter Trials
  52. Chapter 46: Multiple Endpoints
  53. Chapter 47: Multiple Risk Factor Intervention Trial
  54. Chapter 48: N-of-1 Randomized Trials
  55. Chapter 49: Noninferiority Trial
  56. Chapter 50: Nonrandomized Trials
  57. Chapter 51: Open-Labeled Trials
  58. Chapter 52: Optimizing Schedule of Administration in Phase I Clinical Trials
  59. Chapter 53: Partially Balanced Designs
  60. Chapter 54: Phase I/II Clinical Trials
  61. Chapter 55: Phase II/III Trials
  62. Chapter 56: Phase I Trials
  63. Chapter 57: Phase II Trials
  64. Chapter 58: Phase III Trials
  65. Chapter 59: Phase IV Trials
  66. Chapter 60: Phase I Trials in Oncology
  67. Chapter 61: Placebos
  68. Chapter 62: Planning a Group-Randomized Trial
  69. Chapter 63: Postmenopausal Estrogen/Progestin Interventions Trial (PEPI)
  70. Chapter 64: Preference Trials
  71. Chapter 65: Prevention Trials
  72. Chapter 66: Primary Efficacy Endpoint
  73. Chapter 67: Prognostic Variables in Clinical Trials
  74. Chapter 68: Randomization Procedures
  75. Chapter 69: Randomization Schedule
  76. Chapter 70: Repeated Measurements
  77. Chapter 71: Simple Randomization
  78. Chapter 72: Subgroups
  79. Chapter 73: Superiority Trials
  80. Chapter 74: Surrogate Endpoints
  81. Chapter 75: TNT Trial
  82. Chapter 76: UGDP Trial
  83. Chapter 77: Women’s Health Initiative Hormone Therapy Trials
  84. Chapter 78: Women’s Health Initiative Dietary Modification Trial: Update and Application of Biomarker Calibration to Self-Report Measures of Diet and Physical Activity
  85. Index

Frequently asked questions

Yes, you can cancel anytime from the Subscription tab in your account settings on the Perlego website. Your subscription will stay active until the end of your current billing period. Learn how to cancel your subscription
No, books cannot be downloaded as external files, such as PDFs, for use outside of Perlego. However, you can download books within the Perlego app for offline reading on mobile or tablet. Learn how to download books offline
Perlego offers two plans: Essential and Complete
  • Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
  • Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.5M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Both plans are available with monthly, semester, or annual billing cycles.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1.5 million books across 990+ topics, we’ve got you covered! Learn about our mission
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more about Read Aloud
Yes! You can use the Perlego app on both iOS and Android devices to read anytime, anywhere — even offline. Perfect for commutes or when you’re on the go.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app
Yes, you can access Methods and Applications of Statistics in Clinical Trials, Volume 1 by Narayanaswamy Balakrishnan, N. Balakrishnan in PDF and/or ePUB format, as well as other popular books in Medicine & Biostatistics. We have over 1.5 million books available in our catalogue for you to explore.